SCN2A and epilepsy: While most studies are focusing primarily on SCN1A and only investigating Nav1.1 in vitro, Tidball et al. have developed iPSC lines from epilepsy patients with SCN2A and SCN8A LOF mutations for prospective studies (Kim et al. 2018; Tidball et al. 2017).